|
Organization and Summary of Significant Accounting Policies (Details) (USD $)
|
12 Months Ended | 12 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2011
|
Dec. 31, 2013
Minimum [Member]
|
Dec. 31, 2013
Maximum [Member]
|
Dec. 31, 2013
The 1996 Plan [Member]
|
Dec. 31, 2013
The 2002 Plan [Member]
|
Dec. 31, 2013
Stock Incentive Plan1996 And2002 [Member]
|
Dec. 31, 2013
Stock Incentive Plan1996 And2002 [Member]
Minimum [Member]
|
Dec. 31, 2013
Stock Incentive Plan1996 And2002 [Member]
Maximum [Member]
|
Dec. 31, 2013
Cira Biosciences Inc [Member]
|
Dec. 31, 2013
Navidia Biopharmaceuticals Limited [Member]
|
Jun. 25, 2013
General Electric Capital Corporation [Member]
|
Dec. 31, 2013
General Electric Capital Corporation [Member]
|
Dec. 31, 2011
Devicor Medical Products, Inc. [Member]
|
Dec. 31, 2013
Cardinal Health [Member]
|
Dec. 31, 2013
BRE/COH LLC [Member]
|
|
| Organization And Summary Of Accounting Policies [Line Items] | |||||||||||||||||
| Sales Revenue, Goods, Net, Percentage | 96.00% | ||||||||||||||||
| Ownership percentage | 90.00% | 100.00% | |||||||||||||||
| Fair value of notes payable | $ 29,900,000 | ||||||||||||||||
| Shares authorized under share-based compensation plan | 1,500,000 | 12,000,000 | |||||||||||||||
| Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 1 year | 4 years | |||||||||||||||
| Share Based Compensation Arrangement By Share Based Payment Award Options Expiration Term | 10 years | ||||||||||||||||
| Share Based Compensation Arrangement By Share Based Payment Award Options Expiration Term In Certain Cases | 90 days | ||||||||||||||||
| Receivables Percentage | 22.00% | 69.00% | |||||||||||||||
| Estimated useful lives, property and equipment | 3 years | 7 years | |||||||||||||||
| Estimated useful lives, patent costs | 5 years | 15 years | |||||||||||||||
| Debt issuance costs | 593,000 | 881,000 | 691,000 | ||||||||||||||
| Amortization of deferred debt issuance costs | 309,000 | 296,000 | 2,000 | ||||||||||||||
| Deferred debt issuance costs | 691,000 | 295,000 | |||||||||||||||
| Estimated tax liability from gain on sale of discontinued operation | 6,700,000 | ||||||||||||||||
| Estimated tax liability from income of discontinued operation | 1,200,000 | ||||||||||||||||
| Benefit from income taxes | $ 0 | $ 0 | $ 7,880,143 | ||||||||||||||